{"id":802442,"date":"2025-01-21T06:12:06","date_gmt":"2025-01-21T11:12:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"},"modified":"2025-01-21T06:12:06","modified_gmt":"2025-01-21T11:12:06","slug":"regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","title":{"rendered":"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Jan. 21, 2025<\/span><\/span> \/PRNewswire\/ — Robbins Geller Rudman<\/span> & Dowd LLP<\/a><\/b> announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023<\/span> and October 30, 2024<\/span>, inclusive (the “Class Period”), have until March 10, 2025<\/span> to seek appointment as lead plaintiff of the Regeneron <\/i>class action lawsuit. Captioned\u00a0Radtke v. Regeneron Pharmaceuticals, Inc.<\/i>, No. 25-cv-00145 (S.D.N.Y.), the Regeneron <\/i>class action lawsuit charges Regeneron as well as certain of Regeneron’s top current and former executives with violations of the Securities Exchange Act of 1934.<\/p>\n

\n

\n
\n \"Robbins
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n If you suffered substantial losses and wish to serve as lead plaintiff of the Regeneron <\/i>class action lawsuit, please provide your information here:<\/b>\n <\/p>\n

\n
\n https:\/\/www.rgrdlaw.com\/cases-regeneron-pharmaceuticals-inc-class-action-lawsuit-regn.html<\/a>
\n <\/b>\u00a0<\/p>\n

\n You can also contact attorneys J.C. Sanchez<\/a> or Jennifer N. Caringal<\/span><\/a> of Robbins Geller by calling 800\/449-4900 or via e-mail at info@rgrdlaw.com<\/a>.<\/b>\n <\/p>\n

\n CASE ALLEGATIONS<\/b>: Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.\u00a0 According to the Regeneron<\/i> class action lawsuit, one of Regeneron’s primary products is Eylea, an injection to treat age-related macular degeneration, among other conditions.<\/p>\n

The Regeneron<\/i> class action lawsuit alleges<\/span> that defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (i) Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card; (ii) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (iii) as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (iv) because retina practices were sensitive to higher prices when using credit cards to purchase anti-vascular endothelial growth factor (“anti-VEGF”) medications, Regeneron’s price concessions provided a competitive advantage; (v) consequently, Regeneron misleadingly boosted reported Eylea sales; (vi) by failing to report its payment of credit card fees as price concessions, Regeneron overstated the Average Sales Price (“ASP”) reported to federal agencies, thereby violating the False Claims Act; and (vii) as a result of the foregoing, defendants’ positive statements about Regeneron’s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>\n

The Regeneron<\/i> class action lawsuit further alleges<\/span> that on April 10, 2024<\/span>, the U.S. Department of Justice (“DOJ”) announced it had filed a complaint against Regeneron under the False Claims Act for failing to report millions of dollars in discounts provided to drug distributors in the form of reimbursed credit card fees.\u00a0 As a result, the DOJ alleges<\/span> that Eylea’s ASP was inflated, which inappropriately increased Medicare reimbursement, and by reimbursing credit card fees, Regeneron subsidized the treatment costs, thereby gaining a competitive advantage over other anti-VEGF treatment, the Regeneron<\/i> class action lawsuit alleges<\/span>.\u00a0 On this news, the price of Regeneron stock fell, according to the complaint.<\/p>\n

Then, on October 31, 2024<\/span>, the Regeneron<\/i> class action lawsuit further alleges<\/span> that Regeneron announced its third quarter 2024 financial results, revealing lagging U.S. net sales for Eylea and Eylea HD.\u00a0 Specifically, as the Regeneron <\/i>class action lawsuit alleges<\/span>, Regeneron reported sales had only increased 3% versus the third quarter 2023, quarterly sales of Eylea HD were only $392 million<\/span>, missing consensus estimates of $415 million<\/span> to $425 million<\/span>, and “[n]et product sales of EYLEA in the third quarter of 2024 were adversely impacted by a lower net selling price compared to the third quarter of 2023.”\u00a0 On this news, the price of Regeneron stock fell more than 9%, according to the complaint.<\/p>\n

\n THE LEAD PLAINTIFF PROCESS<\/b>: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Regeneron securities during the Class Period to seek appointment as lead plaintiff in the Regeneron <\/i>class action lawsuit.\u00a0 A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.\u00a0 A lead plaintiff acts on behalf of all other class members in directing the Regeneron <\/i>class action lawsuit.\u00a0 The lead plaintiff can select a law firm of its choice to litigate the Regeneron <\/i>class action lawsuit.\u00a0 An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Regeneron <\/i>class action lawsuit.<\/p>\n

\n ABOUT ROBBINS GELLER<\/b>: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud<\/span> cases.\u00a0 Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors.\u00a0 We recovered $6.6 billion<\/span> for investors in securities-related class action cases \u2013 over $2.2 billion<\/span> more than any other law firm in the last four years.\u00a0 With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever \u2013 $7.2 billion<\/span> \u2013 in In re Enron Corp. Sec. Litig.<\/i>\u00a0 Please visit the following page for more information:<\/p>\n

\n
\n https:\/\/www.rgrdlaw.com\/services-litigation-securities-fraud<\/span>.html<\/a>
\n <\/b>\n <\/p>\n

Past results do not guarantee future outcomes.\u00a0<\/p>\n

Services may be performed by attorneys in any of our offices.\u00a0<\/p>\n

Contact:<\/p>\n

Robbins\u00a0Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal<\/span>
655 W. Broadway, Suite 1900, San Diego, CA<\/span> 92101
800-449-4900
info@rgrdlaw.com<\/a><\/b>\u00a0<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302354911.html<\/a><\/p>\n

SOURCE Robbins Geller Rudman & Dowd LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO , Jan. 21, 2025 \/PRNewswire\/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”), have until March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned\u00a0Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron as well as certain of Regeneron’s top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Regeneron class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-regeneron-pharmaceuticals-inc-class-action-lawsuit-regn.html \u00a0 You can also … <\/p>\n

Continue reading “REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-802442","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nREGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , Jan. 21, 2025 \/PRNewswire\/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”), have until March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned\u00a0Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron as well as certain of Regeneron’s top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Regeneron class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-regeneron-pharmaceuticals-inc-class-action-lawsuit-regn.html \u00a0 You can also … Continue reading "REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-21T11:12:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit\",\"datePublished\":\"2025-01-21T11:12:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\"},\"wordCount\":909,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\",\"name\":\"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"datePublished\":\"2025-01-21T11:12:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , Jan. 21, 2025 \/PRNewswire\/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”), have until March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned\u00a0Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron as well as certain of Regeneron’s top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Regeneron class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-regeneron-pharmaceuticals-inc-class-action-lawsuit-regn.html \u00a0 You can also … Continue reading \"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-21T11:12:06+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit","datePublished":"2025-01-21T11:12:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"},"wordCount":909,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","name":"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","datePublished":"2025-01-21T11:12:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-deadline-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=802442"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802442\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=802442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=802442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=802442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}